Abstract
Stage III non-small-cell lung cancer (NSCLC) has a low 5-year survival rate (less than 30%). In order to have a real chance of im-proving patient survival, both staging and treatment must be of appropriate quality.
During staging, it is important to precisely determine regional lymph node involvement and rule out generalization. PET/CT (positron emission tomography/computed tomography) of the torso is recommended to be used for regional lymph node staging.
Positive findings that alter the stage are to be confirmed bioptically. Treatment is always indicated strictly individually, ideally within multidisciplinary teams; it is multimodal, using multiple therapeutic methods (chemotherapy, radiotherapy, surgery).
For stage III patients, immunotherapy is a promising approach for the future.